Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration

RENO, Nev., Aug. 11, 2026 — Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a preclinical-stage biotechnology company advancing an investigational tissue-restoration platform, announced today that Dr. Brian Pilcher, Ph.D., Chief Medical Officer of Conexeu Sciences, will present at the Controversies & Conversations in Laser & Cosmetic Surgery Symposium, taking place Aug. 14–16, 2026. The meeting brings together dermatologists, facial plastic surgeons, plastic surgeons, and aesthetic medicine specialists to discuss emerging technologies, clinical challenges, and evolving treatment approaches in laser surgery, cosmetic surgery, and aesthetic medicine.

Dr. Pilcher will deliver a non-CME industry presentation entitled, "Beyond Filling: An Extracellular Matrix Blueprint for Tissue Regeneration," on Saturday, Aug. 15, 2026 at 12:55 p.m. PT.

The presentation will examine the role of the extracellular matrix (ECM) in tissue regeneration and explore how ECM-based approaches could broaden the scientific framework for regenerative aesthetics beyond traditional volumizing procedures. The presentation aligns with Conexeu's broader efforts to advance tissue-restoration technologies for aesthetic and reconstructive applications through approaches designed to support the body's natural repair and remodeling processes.

Medical aesthetics clinicians and researchers are increasingly examining the ECM as an important component of regenerative aesthetics and tissue health.¹ This reflects a broader scientific focus on how the tissue environment may influence repair, remodeling, and tissue organization, providing important context for the discussion of regenerative technologies at this event.

"At Conexeu, we're focused on investigating ECM-based approaches designed to work with the body's own biology rather than focusing solely on lost volume," said Dr. Brian Pilcher, Ph.D., Chief Medical Officer of Conexeu Sciences. "I'm looking forward to discussing the role of the extracellular matrix in tissue regeneration and why we believe scaffold biology could represent an important shift in how the field thinks about tissue restoration."

Additional information about Controversies & Conversations in Laser & Cosmetic Surgery, including the conference agenda, is available at www.skincarecontroversies.com.

About Conexeu Sciences Inc.

Architecting BioregenerationTM. Conexeu Sciences is a preclinical-stage regenerative tissue platform company. Our patented extracellular matrix (ECM) platform, CXU™, is built on a single structural principle and is designed to support bioregeneration: one formula, one device, designed to scale across multiple addressable markets.

Conexeu is targeting large, multi-billion-dollar end markets, including wound care, periodontal applications, and facial and body tissue restoration, including the tissue changes that can follow GLP-1 weight loss, with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market. The Company is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review.

Conexeu is led by an experienced leadership team with deep expertise in biomaterials, regenerative medicine, and medical device commercialization and development.

About CXU™ CXU™ is designed to support soft tissue lost through injury, aging, and the tissue changes that can follow GLP-1 weight loss. The Company's lead device candidate, Ten-Minute Tissue™, is a thermosensitive extracellular matrix (ECM) that remains fluid at room temperature and is designed to transition to a stable gel in situ at body temperature within approximately ten minutes. In preclinical research, Ten-Minute Tissue™ has been characterized for host cell infiltration, vascular ingrowth, organized remodeling, and a low-inflammatory profile, conditions intended to support constructive remodeling.2

The platform is grounded in more than a decade of university preclinical research and protected by a multi-jurisdictional patent estate spanning more than 40 jurisdictions (U.S., EU, Japan, and Australia, with protection pending in Canada). Conexeu owns the platform IP, holding all rights, title, and interest, with no royalty or licensing obligations, and intends to expand across new indications and markets.

Conexeu is led by an experienced leadership team with deep expertise in biomaterials, regenerative medicine, and medical device commercialization and development.

Media Contact

Gateway Group [email protected] 949.574.3860

Cautionary Statement

CXU™ and the Company's device candidates, including Ten-Minute Tissue™, are investigational and have not been cleared or approved by the U.S. Food and Drug Administration, licensed or authorized for sale by Health Canada, or otherwise authorized for commercial use by any regulatory authority.